Clinical Trials Directory

Trials / Completed

CompletedNCT00618254

A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
All
Age
19 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to assess bioequivalence of a potential generic 1 mg granisetron tablet formulation compared with Roche Laboratories' 1 mg granisetron tablet, Kytril, following a single 1 mg dose, under fasting conditions.

Conditions

Interventions

TypeNameDescription
DRUGGranisetron

Timeline

Start date
2005-03-01
Primary completion
2005-04-01
Completion
2005-04-01
First posted
2008-02-19
Last updated
2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00618254. Inclusion in this directory is not an endorsement.

A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Und (NCT00618254) · Clinical Trials Directory